Abstract 1579P
Background
The US Surveillance, Epidemiology, and End Result (SEER) data indicated an increasing incidence of early-onset GI tract cancers. According to published data, the treatment outcomes of young adults (YA) are comparable to the general population. We aimed to analyze the clinicopathological characteristics and overall survival (OS) of YA treated in a comprehensive cancer center.
Methods
Patients diagnosed with oesophagal (OC), oesophagogastric junction (OGJ), or gastric (GC) cancer between 2010 and 2022 were retrospectively identified from the Masaryk Memorial Cancer Institute database. Inclusion criteria were 1) age 18-50 years, 2) histology, and 3) treatment according to international recommendations.
Results
The consecutive patient cohort included 1725 patients, of which 162 met the inclusion criteria, representing approximately 10% of YA patients from the Czech Republic. In 63% of cases, the patients were men, significantly older than women (84% vs 65% in the age group 40-49 years, p=0.005). In women, tumors were more often located in the stomach (78% vs 53%, p=0.001) and primary metastatic (67% vs 50%, p=0.039). Six patients had localized disease (stage I), 36 (16 OC/OGJ, 20 GC) underwent radical resection, 31 (15 OC/OGJ, 16 GC) were unresectable, and 86 metastatic (25 OC/OGJ, 61 GC). With a median follow-up of 67 months, 131 (81%) deaths were recorded. Radically resected patients achieved a median OS of 54 mo with a 5-year OS of 42%, whereas the median OS for the unresectable and metastatic disease was 11 mo, and 8.6 mo, respectively.
Conclusions
In our YA cohort, men were older, while women were more likely to have metastatic gastric cancer. OS for the locally advanced disease was comparable to published studies observing the general population but noticeably shorter for metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1569P - The CODRP model for predicting drug sensitivity in patient-derived 3D gastric cancer cells
Presenter: Dong Woo Lee
Session: Poster session 22
1571P - Exploration of immune and metabolism gene signature for prognosis of esophageal carcinoma and establishment of a combined prediction model
Presenter: Hao Wu
Session: Poster session 22
1572P - Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers
Presenter: Antonella Cammarota
Session: Poster session 22
1573P - Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC
Presenter: Baosheng Li
Session: Poster session 22
1575P - Factors associated with uptake of adjuvant nivolumab in a nationwide esophageal cancer patient cohort
Presenter: Rob Verhoeven
Session: Poster session 22
1577P - Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response
Presenter: Chang Gon Kim
Session: Poster session 22
1578P - Effect of immune checkpoint inhibitors in metastatic gastric cancer: A real-world evidence study
Presenter: Francesco Puccetti
Session: Poster session 22